Cargando…
Phase I study of irinotecan and raltitrexed in patients with advanced astrointestinal tract adenocarcinoma
To determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of irinotecan and raltitrexed given as sequential short infusions every 3 weeks, 33 patients with pretreated gastrointestinal adenocarcinoma (31 colorectal, 2 oesophagogastric) entered this open label dose-escalation st...
Autores principales: | Ford, H E R, Cunningham, D, Ross, P J, Rao, S, Aherne, G W, Benepal, T S, Price, T, Massey, A, Vernillet, L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363476/ https://www.ncbi.nlm.nih.gov/pubmed/10901362 http://dx.doi.org/10.1054/bjoc.2000.1192 |
Ejemplares similares
-
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma
por: Ulrich-Pur, H, et al.
Publicado: (2003) -
Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer
por: Feliu, J, et al.
Publicado: (2005) -
A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma
por: Eatock, M M, et al.
Publicado: (2000) -
Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study
por: Feliu, J, et al.
Publicado: (2004) -
Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
por: Liu, Min, et al.
Publicado: (2020)